

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER Medical Holdings Limited
希瑪醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3309)

COMPLETION ANNOUNCEMENT

References are made to the announcements of C-MER Medical Holdings Limited (the “**Company**”) dated 20 May 2026 and 30 June 2026 (the “**Announcements**”) in relation to the subscription for and acquisition of share capital of CHIGENOV Co., Ltd. (北京中因科技股份有限公司) (the “**Target Company**”). Unless the context requires otherwise, the capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As of the date of this announcement, HK (International) Eye Care has entered into the Legally Binding Agreement with the Target Company as one of the transaction documents. The Legally Binding Agreement stipulated, among other things, (i) the grant of the Exclusive Rights on a perpetual basis upon the fulfillment of conditions precedent, namely the obtaining of the approval from NMPA and that of local authorities in Hong Kong and Macau; (ii) the revenue allocation to the Group shall be no less favourable to the Group than any similar agreement entered into or to be entered into by the Target Company in relation to the application of ZVS101e, and (iii) any dispute arising out of or in connection with such agreement shall be referred to mediation at Hong Kong International Arbitration Centre (HKIAC) and in accordance with its then current mediation rules.

The Board is pleased to further announce that all conditions precedent under the C-MER Series B Investment Agreement and each of the Share Purchase Agreements have been satisfied or waived (as the case may be) and that completion of the C-MER Series B Investment and the Share Purchases have taken place as of the date of this announcement. Upon completion of all of the Transactions, (i) HK (International) Eye Care owned 996,070 shares, representing approximately 10.23% of the enlarged issued share capital, of the Target Company and (ii) the Company will not consolidate the financial performance of the Target Company into its financial statements from the accounting perspective.

By order of the Board
C-MER Medical Holdings Limited

Ms. LI Xiaoting

Vice Chairman, Executive Director and Chief Executive Officer

Hong Kong, 10 August 2026

As at the date of this announcement, the Board comprises its chairman and independent non-executive Director, Dr. Rex AU YEUNG Pak-kuen; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.